CN110408602B - Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 - Google Patents
Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 Download PDFInfo
- Publication number
- CN110408602B CN110408602B CN201910710760.4A CN201910710760A CN110408602B CN 110408602 B CN110408602 B CN 110408602B CN 201910710760 A CN201910710760 A CN 201910710760A CN 110408602 B CN110408602 B CN 110408602B
- Authority
- CN
- China
- Prior art keywords
- pcv2
- prrsv
- seq
- recombinant virus
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 115
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 95
- 229960005486 vaccine Drugs 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims abstract description 91
- 239000000427 antigen Substances 0.000 claims abstract description 66
- 102000036639 antigens Human genes 0.000 claims abstract description 66
- 108091007433 antigens Proteins 0.000 claims abstract description 66
- 241001673669 Porcine circovirus 2 Species 0.000 claims abstract description 63
- 239000013598 vector Substances 0.000 claims abstract description 32
- 239000012620 biological material Substances 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 8
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 20
- 244000005700 microbiome Species 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 230000002458 infectious effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 239000012646 vaccine adjuvant Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000644 propagated effect Effects 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 101150044789 Cap gene Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 abstract description 10
- 230000000890 antigenic effect Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 230000010076 replication Effects 0.000 abstract description 3
- 238000005096 rolling process Methods 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 230000003053 immunization Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000001976 enzyme digestion Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 229940023832 live vector-vaccine Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000282887 Suidae Species 0.000 description 6
- 210000003855 cell nucleus Anatomy 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000011076 safety test Methods 0.000 description 4
- 108700026220 vif Genes Proteins 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 241000710788 Lelystad virus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 3
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001292006 Arteriviridae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 241001533384 Circovirus Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- -1 but not limited to Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10041—Use of virus, viral particle or viral elements as a vector
- C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
编号 | 序列 |
SEQ ID NO.11 | TCCAGGACGACCTCACGTT |
SEQ ID NO.12 | TCATCGTGTGCGGCACGCGCCG |
酶切纯化产物 | 2μL |
pBluescript SKⅡ(+)酶切纯化产物 | 1μL |
10×连接酶缓冲液 | 1μL |
T4 DNA连接酶 | 1μL |
三蒸水 | 5μL |
pBluescriptⅡPCV2-PRRSV | 3μL |
Nde I | 1μL |
10×Buffer | 5μL |
三蒸水 | 11μL |
引物 | 序列(5'-3') | 编号 |
Forward1 | AAGGGCTGGGTTATGGTATG | SEQ ID NO.13 |
Reverse2 | CGCTGGAGAAGGAAAAATGG | SEQ ID NO.14 |
5×RT Buffer | 12μL |
10mmol/L dNTPs | 4μL |
50μmol/L Oligo(dT) | 1μL |
AMV反转录酶(10U/μL) | 1μL |
总RNA | 2μL |
10×PCR Buffer | 5μL |
10mmol/L dNTPs | 1μL |
25μmol/L上、下游引物各 | 1μL |
cDNA | 2μL |
Taq DNA聚合酶 | 2.5U |
加三蒸水至 | 50μL |
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910710760.4A CN110408602B (zh) | 2019-08-02 | 2019-08-02 | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910710760.4A CN110408602B (zh) | 2019-08-02 | 2019-08-02 | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110408602A CN110408602A (zh) | 2019-11-05 |
CN110408602B true CN110408602B (zh) | 2021-03-19 |
Family
ID=68365463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910710760.4A Active CN110408602B (zh) | 2019-08-02 | 2019-08-02 | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110408602B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458280A (zh) * | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 两个人工合成prrs病毒多表位串联核苷酸序列及应用 |
CN1800375A (zh) * | 2005-12-23 | 2006-07-12 | 南京农业大学 | 猪繁殖与呼吸综合征与猪圆环病毒重组腺病毒及疫苗 |
CN103059142A (zh) * | 2012-12-17 | 2013-04-24 | 重庆市畜牧科学院 | 猪圆环病毒的抗原和猪繁殖与呼吸综合征病毒的抗原的重组蛋白及其制备方法与应用 |
CN103648527A (zh) * | 2011-12-30 | 2014-03-19 | 美国联合生物医学公司 | 有效控制猪繁殖与呼吸综合征(prrs)的基于合成肽的标记疫苗和诊断*** |
CN106442968A (zh) * | 2016-09-21 | 2017-02-22 | 福建省农业科学院畜牧兽医研究所 | 猪繁殖与呼吸综合征血清学鉴别诊断试剂盒 |
CN107847575A (zh) * | 2015-06-01 | 2018-03-27 | 瑞宝基因股份有限公司 | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 |
KR20190023604A (ko) * | 2017-08-29 | 2019-03-08 | 주식회사 옵티팜 | 바이러스 유사입자 기반의 복합백신 |
CN109554375A (zh) * | 2018-12-13 | 2019-04-02 | 郑州大学 | 美洲型prrsv n蛋白抗原表位及其应用 |
-
2019
- 2019-08-02 CN CN201910710760.4A patent/CN110408602B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458280A (zh) * | 2003-06-02 | 2003-11-26 | 中国农业科学院哈尔滨兽医研究所 | 两个人工合成prrs病毒多表位串联核苷酸序列及应用 |
CN1800375A (zh) * | 2005-12-23 | 2006-07-12 | 南京农业大学 | 猪繁殖与呼吸综合征与猪圆环病毒重组腺病毒及疫苗 |
CN103648527A (zh) * | 2011-12-30 | 2014-03-19 | 美国联合生物医学公司 | 有效控制猪繁殖与呼吸综合征(prrs)的基于合成肽的标记疫苗和诊断*** |
CN103059142A (zh) * | 2012-12-17 | 2013-04-24 | 重庆市畜牧科学院 | 猪圆环病毒的抗原和猪繁殖与呼吸综合征病毒的抗原的重组蛋白及其制备方法与应用 |
CN107847575A (zh) * | 2015-06-01 | 2018-03-27 | 瑞宝基因股份有限公司 | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 |
CN106442968A (zh) * | 2016-09-21 | 2017-02-22 | 福建省农业科学院畜牧兽医研究所 | 猪繁殖与呼吸综合征血清学鉴别诊断试剂盒 |
KR20190023604A (ko) * | 2017-08-29 | 2019-03-08 | 주식회사 옵티팜 | 바이러스 유사입자 기반의 복합백신 |
CN109554375A (zh) * | 2018-12-13 | 2019-04-02 | 郑州大学 | 美洲型prrsv n蛋白抗原表位及其应用 |
Non-Patent Citations (3)
Title |
---|
Expression of antigenic epitopes of porcine reproductive andrespiratory syndrome virus (PRRSV) in a modified live-attenuatedporcine circovirus type 2 (PCV2) vaccine virus (PCV1-2a) as apotential bivalent vaccine against both PCV2 and PRRSV;Pablo E. Pineyro等;《Virus Research》;20150731;第210卷;摘要;第155页左栏最后1段 * |
Generation and immunogenicity of porcine circovirus type 2 chimericvirus-like particles displaying porcine reproductive and respiratorysyndrome virus GP5 epitope B;Gaowei Hu等;《Vaccine》;20160228;第34卷;全文 * |
The primary GP5 neutralization epitope of North American isolates of porcine reproductive and respiratory syndrome virus;Peter G.W.Plagemann;《Veterinary Immunology and Immunopathology》;20041231;第102卷;摘要第10-12行 * |
Also Published As
Publication number | Publication date |
---|---|
CN110408602A (zh) | 2019-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112076315A (zh) | 新冠病毒s蛋白和铁蛋白亚基融合的纳米抗原颗粒、新冠疫苗及其制备方法和应用 | |
CN109762792B (zh) | 一种猪繁殖与呼吸综合征病毒嵌合毒株及其应用 | |
CN110551695A (zh) | 非洲猪瘟病毒四基因缺失弱毒株及其应用 | |
CN107841507B (zh) | 一种高效表达的猪圆环病毒2型Cap-穿膜肽融合蛋白基因及其应用 | |
CN110317278B (zh) | Svv和fmdv的融合蛋白及其编码基因、表达载体、细胞系、工程菌和疫苗与应用 | |
CN113461788B (zh) | 猫冠状病毒重组抗原、其基因工程亚单位疫苗及应用 | |
CN111718958B (zh) | 一种兔出血症病毒1型和2型vp60二价重组杆状病毒载体灭活疫苗及其制备方法和应用 | |
CN111534547A (zh) | 一种表达血清4型禽腺病毒纤突蛋白f2的重组杆状病毒的构建方法 | |
CN110452889B (zh) | 一种表达bvdv-e0的重组牛肠道病毒的构建方法与初步应用 | |
CN114163505B (zh) | 猪瘟、猪伪狂犬病毒二联亚单位疫苗及其制备方法 | |
CN103555680A (zh) | 一种具有免疫原性的prrsv病毒样颗粒及其制备与应用 | |
CN112500458B (zh) | 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用 | |
CN113896773A (zh) | 重组fcv抗原及猫嵌杯病毒基因工程亚单位疫苗 | |
CN111454989B (zh) | 一种嵌合型基因i型乙型脑炎病毒病毒样颗粒疫苗及其制备方法和应用 | |
CN107868131A (zh) | 一种猪细小病毒病亚单位疫苗及其制备方法 | |
US11767356B1 (en) | Canine parvovirus nanobody CPV-VHH-E3 and application thereof | |
CN116102660B (zh) | 一种猪细小病毒基因工程表位疫苗及其制备方法 | |
CN110408602B (zh) | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 | |
CN108017714B (zh) | 一株ⅱ型鲤疱疹病毒orf92蛋白的单克隆抗体及其应用 | |
CN109943576A (zh) | 一种嵌合犬瘟热病毒主要免疫基因的重组狂犬病病毒及其应用 | |
CN113425838B (zh) | 重组prrsv病毒样颗粒抗原抗体复合物及其制备方法 | |
CN115141273A (zh) | 一种猫杯状病毒的单克隆抗体及其应用 | |
CN101851631B (zh) | 一种密码子优化的ev71 vp1基因及其核酸疫苗 | |
CN114134180A (zh) | 表达猪蓝耳病毒gp5蛋白的重组杆状病毒的构建方法 | |
CN110305225B (zh) | Sva-pcv2融合蛋白及其制备方法、基因、生物材料、应用和疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 215002 station 6-013, 6th floor, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province (cluster registration) Applicant after: Tiankang Pharmaceutical (Suzhou) Co.,Ltd. Applicant after: TECON BIOLOGICAL Co.,Ltd. Address before: 2-3 / F, building 8, 338 Galileo Road, Shanghai pilot Free Trade Zone, 201210 Applicant before: Tiankang Biology (Shanghai) Co.,Ltd. Applicant before: TECON BIOLOGICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230427 Address after: 830000 Room 201, Building 1, No. 46 Satellite Road, Phase II, Urumqi Economic Development Zone (Toutunhe District), Xinjiang Uygur Autonomous Region Patentee after: Tiankang biopharmaceutical Co.,Ltd. Address before: 215002 station 6-013, 6th floor, No. 88, modern Avenue, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province (cluster registration) Patentee before: Tiankang Pharmaceutical (Suzhou) Co.,Ltd. Patentee before: TECON BIOLOGICAL Co.,Ltd. |